AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00659958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: 300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
Study NCT02418312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: histamine-2 receptor antagonist
Description: famotidine 40 mg qd plus thienopyridine
Study NCT02418312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo plus thienopyridine
Study NCT02104271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation
Description: APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos.
Study NCT02104271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Historical control
Description: APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos.
Study NCT04019067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MCE first
Description: Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours.
Study NCT01698918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
Study NCT00622947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right temporal low frequency (1 hz) rTMS
Description: Right temporal low frequency (1 hz) rTMS.
Study NCT01698918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
Study NCT01698918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
Study NCT01698918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)
Description: Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
Study NCT01698918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care to treat stomatitis (Stomatitis sub-study)
Description: Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
Study NCT04413526 — intervention group
Intervention type: PROCEDURE
Intervention: radiofrequency
Description: radiofrequency combined with liver resection
Study NCT04413526 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Description: only TACE treatment
Study NCT04413526 — intervention group
Intervention type: PROCEDURE
Intervention: TACE+radiofrequency
Description: TACE followed by radiofrequency
Study NCT02791204 — intervention group
Intervention type: DEVICE
Intervention: SPECT/CT imaging following revascularization procedures
Description: Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
Study NCT00622947 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-rTMS
Description: The coil is angled 90 degrees away from the scalp
Study NCT03483870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: 200 ug morphine sulphate will be injected intrathecally
Study NCT03483870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Description: 200 ug morphine sulphate will be injected intrathecally
Study NCT03483870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL of normal saline 0.9% IV injection
Study NCT04479306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT04474210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 tablets orally.
Study NCT04474210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 tablets orally.
Study NCT03483870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: 2 mL of 2 mg granisetron IV injection
Study NCT02749942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoRIC: Remote Ischemic Conditioning
Description: 4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada
Study NCT02749942 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AutoRIC: Sham device treatment
Description: 4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada
Study NCT01024491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: daily dose of paroxetine 15mg for 12 weeks
Study NCT01024491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: active daily treatment with paroxetine 20 mg
Study NCT01031108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study NCT01031108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SRT2104
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study NCT01694667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
Study NCT01694667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
Study NCT02791204 — intervention group
Intervention type: DEVICE
Intervention: SPECT/CT imaging
Description: Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
Study NCT03176407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HemoPill acute
Description: Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
Study NCT01024491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: active daily treatment with placebo
Study NCT02262078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite Inhalation Solution
Description: 90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
Study NCT02262078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be administered (by inhalation) to participants prior to exercise.
Study NCT03529097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: 2 liters of 0.9% NaCl IV fluids
Study NCT03529097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
Study NCT03529097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optalgin, Voltaren, Morphine
Description: Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
Study NCT03529097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optalgin, Voltaren, Morphine
Description: Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
Study NCT01471418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT with 18-FDG
Description: FDG uptake
Study NCT02630017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD methylphenidate first, placebo second
Description: double-blind, counter-balanced administration
Study NCT02630017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD placebo first, methylphenidate second
Description: double-blind, counter-balanced administration
Study NCT03591588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
Study NCT04186377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
Description: Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing
Study NCT04186377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
Description: Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing
Study NCT04186377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S26E
Description: Daily application of S26E extract on wound site
Study NCT01903902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please Drug-eluting balloon
Description: Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length \< 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
Study NCT04081532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical removal of superficial peritoneal endometriosis
Description: In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
Study NCT01772199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK239512
Description: White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
Study NCT01772199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White to almost white, round tablets. Once daily orally.
Study NCT01473069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853, ketoconazole
Description: JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
Study NCT01473069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: JTK-853 Tablets or Placebo, twice a day for 14 days
Study NCT01473069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JTK-853 or Placebo
Description: JTK-853 Tablets or Placebo, twice a day for 14 days
Study NCT01020097 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluorine F18 EF5
Description: Given IV
Study NCT01020097 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: immunohistochemistry staining method
Description: Correlative study
Study NCT01020097 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Description: Correlative study
Study NCT01020097 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron Emission tomography
Description: Undergo scan
Study NCT03556852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
Study NCT03556852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
Study NCT00958048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation
Description: CPAP, BiPAP
Study NCT02383693 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation
Study NCT02383693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation
Study NCT02630017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-ADHD methylphenidate first, placebo second
Description: double-blind, counter-balanced administration
Study NCT03677167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking on a treadmill
Description: Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
Study NCT03677167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking on a treadmill
Description: Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
Study NCT04089202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eConsult
Description: Completion of electronic consult utilizing data collected from flash glucose monitoring
Study NCT04089202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
Study NCT03279367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Objective speech response detection
Description: Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
Study NCT05309057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Intermittent Fasting
Description: Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
Study NCT02964468 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3DCRT treatment (sequential boost)
Description: Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers.
Study NCT02964468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose Escalation Intensity Modulated Radiotherapy treatment
Description: Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers.
Study NCT03398057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
Study NCT02814409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
Description: IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion
Study NCT02814409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Tenecteplase
Description: IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
Study NCT02176694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
Study NCT02309515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02309515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02309515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02309515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM
Study NCT02309515 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM
Study NCT02684656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: Hemodialysis >/=4h
Study NCT02630017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-ADHD placebo first, methylphenidate second
Study NCT05945056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frog Leg Exercise
Description: The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.